ReviewBMC psychiatry2014
Clozapine: a review of clinical practice guidelines and prescribing trends.
Review in BMC psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02640300 (Switching Antipsychotics), which is not on this map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 236 citations in OpenAlex.
- Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis.Clinical pharmacokinetics · 2023Pooled it
- A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications.Frontiers in pharmacology · 2023Pooled it
- Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.Psychological medicine · 2021Pooled it
- Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017Pooled it
- Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.BMC psychiatry · 2017Pooled it
- Trial
- Enhancing Psychiatry Residents' Knowledge and Comfort With Clozapine Prescribing Through Educational Interventions.Cureus · 2026Article
- The adverse effects of clozapine on blood markers and electrocardiographic findings in patients with schizophrenia.BioMedicine · 2026Article
- Article
- Contrasting Effects of Clozapine and Risperidone on Cholesterol Metabolism, Synaptic Proteins, and Transcriptional Regulation in Human LUHMES Neurons.Molecular neurobiology · 2025Article
- Article
- Declines and pronounced state-level variation in clozapine use among Medicare patients.PloS one · 2025Article
- Evaluating the Role of Clozapine in Treatment-Resistant Schizophrenia: A Narrative Synthesis of Clinical, Economic, and Quality-of-Life Outcomes.Neuropsychiatric disease and treatment · 2025Review
- Article
- A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia.European archives of psychiatry and clinical neuroscience · 2024Article
- Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine.The Journal of clinical psychiatry · 2024Article
- Clozapine clinical toolkit optimizes inpatient clozapine monitoring.The mental health clinician · 2024Article
- Development of an individualized risk calculator of treatment resistance in patients with first-episode psychosis (TRipCal) using automated machine learning: a 12-year follow-up study with clozapine prescription as a proxy indicator.Translational psychiatry · 2024Article
- Alert prescribing of clozapine: a comparison of five drug-drug interaction sources.Therapeutic advances in drug safety · 2024Article
- Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia.Frontiers in health services · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClozapine effectiveness in the treatment of refractory schizophrenia has been sustained by published evidence in the last two decades, despite the introduction of safer options. DISCUSSION: Current clinical practice guidelines have strongly recommended the use of clozapine in treatment-resistant schizophrenia, but prescribing trends do not appear to have followed such recommendations. Clozapine is still underutilized especially in patients at risk of suicide. It seems that physicians are hesitant in prescribing clozapine due to concerns about serious adverse effects. Recent reports have highlighted the need to inform health professionals about the benefits of treating patients with clozapine and have voiced concerns about the underutilization of clozapine especially in patients at risk of suicide. SUMMARY: Guidelines and prescribing patterns reported in various countries worldwide are discussed. Suggestions on how to optimize clozapine utilization have been published but more efforts are needed to properly inform and support prescribers' practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.